Harbour BioMed to Develop Kelun-Biotech's Cancer Immunotherapy Candidate A167

Harbour BioMed will partner with Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize its Phase II cancer immunotherapy candidate A167 worldwide except greater China, through an exclusive collaboration that could generate more than $350 million for Kelun-Biotech, the companies said today.A167 (formerly KL-A167) is an anti-programmed death-ligand 1 (PD-L1) antibody currently in multiple Phase I and Phase II trials in China targeting lymphoma and solid tumors.A167 is designed to bi